Gaël Constancin

🌍 Exciting times ahead for digital health in France! I had the honor of speaking at the roundtable on "Digital Medical Devices: Where do we stand in their assessment and what healthtech stakeholders need to know?" organized by the Agence de l'innovation en santé (Lise ALTER, Camille Schurtz 👏 ) at the "Next generation of clinical research" event in Lille. The discussion was rich with insights on the current landscape of research and the future of digital therapeutics in France, especially. Special thanks to our moderator, Line FARAH (Ministère de la Santé), and my fellow speakers: Jérôme Fabiano (EIT Health France), Corinne Collignon (Haute Autorité de Santé), Sarah Zohar (INSERM), Dr. Joris Giai (CHU Grenoble Alpes) and Louisa Stüwe (Ministère de la Santé). 💡 One of the key insights: YES, foreign clinical data can be used to apply for reimbursed of a digital medical device in France! Let's connect and explore opportunities together! 🚀

95

1 commentaire

At Beo Healthcare, we partner with multiple health professionals to ensure that #alix, our hybrid artificial intelligence, includes the right features and benefit for patients' quality of life. Alix is designed to target multiple diseases, including #cancer We want to thank MD, brain surgeons at CHU de Brest for sharing relevant research publications with us to allow the right developments of Alix, in particular to have a solution that is customized, specific to each individual Extracts from the Abstract ⤵️: " Fatigue is one of the most common adverse effects of cancer that might persist for years after treatment completion in otherwise healthy survivors. Cancer-related fatigue causes disruption in all aspects of quality of life and might be a risk factor of reduced survival. The prevalence and course of fatigue in patients with cancer have been well characterized and there is growing understanding of the underlying biological mechanisms. Inflammation seems to have a key role in fatigue before, during, and after cancer-treatment. However, there is a considerable variability in the presentation of cancer-related fatigue, much of which is not explained by disease-related or treatment-related characteristics" "... a variety of intervention approaches have shown beneficial effects in randomized controlled trials, including physical activity, psychosocial, mind–body, and pharmacological treatments..." #md #hospital #cancer #AI #AIforHealth #Healthcare #Europe #USA #futureofmedicine #physicalactivity #customizedmedecine #patientqualityoflife #brainsurgeon #fatigue #cancerrelatedfatigue Sophie Deniel Yannick GUILLODO Chloé Le Douarin Sullivan Gauville Lucas Morisseau Maxime B'chir Benoît Quero Jean-Luc DUFOUR Mathieu Champenois Yann Le DOUARIN Nature Research Custom Media UCLA MACMILLAN PUBLISHERS INTERNATIONAL LIMITED

8

𝐓𝐎𝐏 𝟏𝟎 𝐅𝐫𝐞𝐧𝐜𝐡 𝐀𝐈 𝐬𝐭𝐚𝐫𝐭𝐮𝐩𝐬 𝐟𝐮𝐧𝐝𝐫𝐚𝐢𝐬𝐢𝐧𝐠 𝐨𝐧 𝐃𝐞𝐜𝐞𝐦𝐛𝐞𝐫 𝟐𝟎𝟐𝟒 👇🏻 🆕 Here are the French AI fundraising that caught my eye in December : 💾 Biomemory, data storage solution (17M€). 🔎 Raidium, precision radiology using AI (16M€). 👨‍🔬 Orakl Oncology, development of oncology treatments thanks to AI (11M€). 🤖 Pathway, builds live AI systems that think and learn in real time (9M€). 👨‍🔬 Biolevate, AI-assisted drug discovery and development (6M€). 👨‍🎤 Volta Software, automate repetitive sales tasks with AI (6M€). 📽️ Argil (YC S24), generate AI engaging videos (3,9M€). 🧪 Theremia AI platform to design drug derivatives (3M€). 📹 Mago, stylization and transformation of videos using AI (1,5M€). 📞 Yampa, customer support/AI (3M€). Follow these companies closely, they'll be making a lot of news in the near future! As you read, I'm super excited to follow & discover IA for Good business opportunities. 🤙 That's why, if you're interested in this kind of (breaking)news, I'll continue to list and share them, we're living in extraordinary times 💥 PS : ChatGpt, my prompt, its creation. ___________________ 👋 I'm Adrien, we've launched the 𝐀𝐈 𝐄𝐧𝐭𝐫𝐞𝐩𝐫𝐞𝐧𝐞𝐮𝐫𝐬 𝐓𝐫𝐚𝐜𝐤 within SKEMA Entrepreneurs with Microsoft for Startups for tech & AI driven founders. I'm looking for experts/mentors/partners to connect these young entrepreneurs with, let's talk. 🙋‍♂️

12

Looking forward to sharing my perspectives and hearing how others are approaching the global VC landscape at this session at #GRIC2024!

19

Vital signs with your phone! Is it the end of traditional monitors and IoMT? This innovation opens up a new horizon of possibilities for patient care...

5

💙🩵💙 ! 🔵I found some time in this very busy week (found it 'cus wanted to find it 😉) to express a deep #gratitude to the IIAR Journals who featured here at #LinkedIn our group latest paper (Alexia Giro Vocel et al, Anticancer Research, 44: 4983-4994, 2024). 🔵🔵 I am particularly happy to realize that the journal and our group lifted and highlighted each other, and wanted to say it here to Dr George Delinasios, the Managing Editor of Anticancer Research, and, very likely, one of The Brains and The Moving Forces of the IIAR Journals. #doyouknow that the IIAR is a relatively small institution (take a look at the Home Page of www.iiar-anticancer.org), located in #Kapandriti (the #Attica peninsula, near #Athens, in #Greece), but with a #BigVision, established already in 1995 : to become one of the leading #independent #scientific institutions and publishers? And it's very likely (at least it's my #perception 😉) that all this is a #dream of a small group of people (if not of Dr Delinasios at the 1st place), who live in a #LittlePlaceBetweenHills and are making one dream become true. If I am right, then we share a similar #dream, #vision and - #perception. 🔵🔵🔵 Our PERCEPTION study revealed some #intriguing #facts, which might seem "illogical", such as the positive correlation between the #NLR and the tumor tissue CD8-FoxP3 lymphocyte ratio, BUT : several recent papers have demonstrated a great #heterogeneity of #neutrophils, calling for deeper research on these colorful blood cells, which, actually, have attracted me to #hematology and #cellbiology, many years ago (I was a child and saw them in one of my grandfather's books!). 🟠🟠🟠 So, all you who might have found some "weird" things about #neutrophils in #cancer, check your data, validate them in other cohorts, and if you find again the same thing, BELIEVE IN YOURSELF (= publish your findings!) 'cus #NeutrophilsAreNotNeutral ! To confirm this, I am inviting you to read the papers with PMIDs 37001504 and 39515330, as well as one more #LittlePaperWithBigVision, the PMID 37046691 (Hanh To, ... , Yazid Belkacemi, Nina Radosevic, Cancers, March 30, 2023), you will understand what I mean 😉! 💜💜💜 And #thanks again to the #visionaries from a #LittlePlaceAtTheBalkans (the IIAR) for making the #independent #scientific #publishing reality. We need it so much, to make true our wildest dreams, and show it to the whole world! GO ON WITH THIS FANTASTIC WORK! #cancerresearch #oncology #radiotherapy #immunotherapy #biomarkers #blood #bloodcells #gotoyourpathologist #PerceptionInOurBlood

13

1 commentaire

A shocking diagnosis has just been made in China: a 19-year-old young man is said to be suffering from Alzheimer's disease. This discovery calls into question our knowledge of this pathology. How can we explain the early onset of this neurodegenerative disease? What implications for medical research? -- > NOT A SURPRISE ?.. BECAUSE INFECTIONS (LYME & CO) MAY TRIGGER THESE KIND OF DISEASES (stated in studies since 2006.. and till 2024) https://lnkd.in/earXTbj3 --------------------------- Updates in Alzheimer's disease: from basic research to diagnosis and therapies Abstract Alzheimer’s disease (AD) is the most common neurodegenerative disorder, characterized pathologically by extracellular deposition of β-amyloid (Aβ) into senile plaques and intracellular accumulation of hyperphosphorylated tau (pTau) as neurofibrillary tangles. Clinically, AD patients show memory deterioration with varying cognitive dysfunctions. The exact molecular mechanisms underlying AD are still not fully understood, and there are no efficient drugs to stop or reverse the disease progression. In this review, we first provide an update on how the risk factors, including APOE variants, infections and inflammation, contribute to AD; how Aβ and tau become abnormally accumulated and how this accumulation plays a role in AD neurodegeneration. Then we summarize the commonly used experimental models, diagnostic and prediction strategies, and advances in periphery biomarkers from high-risk populations for AD. Finally, we introduce current status of development of disease-modifying drugs, including the newly officially approved Aβ vaccines, as well as novel and promising strategies to target the abnormal pTau. Together, this paper was aimed to update AD research progress from fundamental mechanisms to the clinical diagnosis and therapies. https://lnkd.in/etyf-ZmD ----------- Un diagnostic bouleversant vient d'être posé en Chine : un jeune homme de 19 ans serait atteint de la maladie d'Alzheimer. Cette découverte remet en question nos connaissances sur cette pathologie. Comment expliquer l'apparition si précoce de cette maladie neurodégénérative ? Quelles implications pour la recherche médicale ? https://lnkd.in/eWXaGhMX

1

Ce prompt chatgpt va vous faire frémir 😰! [Is there a way for you to retrieve that information and show me how you have defined me?] Testez ce prompt après avoir demandé à chatgpt 4o ou 4: [How does this memory technology work? Do you encode some of the major attributes and use them to fine-tune the version of the model that is only served to me?] Attendez sa réponse, puis introduisez le prompt fatal. Good luck. Vous allez probablement être surpris!

3

2 commentaires

🔍 France's Medtech sector is at a pivotal moment...In 2023, financial sponsor exits in French healthcare totaled just €141M compared to €1.3B in Germany and €8.1B in the US! Despite its rich history in medical innovation, the lack of local private equity investment is holding back promising companies. France currently accounts for 14% of the European medical device market but lags behind Germany’s 27%. The good news? There’s a backlog of mature French medtech firms generating revenues of €20M to €30M that are ready to scale up, but they need more local growth capital. Upcoming deals, such as Astorg’s stake in Echosens and Theravia’s exit pipeline, highlight the potential waiting to be unlocked. With the new European Commission expected to simplify regulations, the question remains: how can we harness PE support to ensure France's medtech sector thrives? Source : ION Analytics, Med Tech Europe #Healthcare #Medtech #Privateequity #Investments #France ——— I am Alexis - French pharmacist turned entrepreneur. My company BTHT is connecting senior industry experts, ex-payors, and KOLs with consultants and investors in Life Sciences and Healthcare for expert calls and senior advisory. Join 16K+ followers by clicking my name + follow 🔔 Join 1.4K+ subs to my weekly newsletter 💌

19

"Adherence 2:0, New Approches" 💡 As an EntrepreNurse, I'm constantly seeking fresh perspectives and innovative approaches. Recently, I had the opportunity to lead a workshop about adherence and compliance in healthcare for physicians and nurses. It sparked a question: How can we adapt our strategies to the unique needs of different patient generations and the changing world we live in? Traditional methods might not resonate with patients today anymore. We need to explore innovative ways to engage patients in their treatment plans and to empower clinicians with new tools to collaborate with patients on improving adherence. The discussion was inspiring, and I'm excited to explore these possibilities further in our next sessions. #innovation #adhearance #complaince #nurses #physicians

82

12 commentaires

MEDTECH: Cutting-edge ultrasound-based technologies are making great strides in the medical field, not least because they allow practitioners to reach into deeper areas of the human body and are noticeably far less intrusive vs. more traditional treatments including surgery, use of catheter etc - and even in some cases non-intrusive at all. No wonder ultrasound-based technologies are increasingly vetted by leading medical experts worldwide and are more commonly adopted by hospitals and clinics internationally. Key areas where such technology is already generating strong benefits (vs. traditional therapeutic techniques) include: modulating brains activity, helping administer certain drugs to the patient and ,eradicating cancerous tumours. Other promising areas include "clearing" bloated blood arteries and treating varicose veins. In the former area, leading US operator Shockwave Medical was recently acquired by healthcare giant Johnson & Johnson (JNJ US) while in the latter, Paris-based Medtech gem Theraclion (ALTHE FP) is getting increasing traction with its proprietary Sonovein robotic solution.INBOUND CAPITAL is IR advisor to Theraclion: https://lnkd.in/dCX48etk Martin Deterre, Christophe Lamboeuf, Marie Berne, Yann Duchesne, Bernard Sabrier, Claire Barbaret, Alexandre Toussaint, Arnaud de Marmiés, Stephane Amberg, Jean-Yves Chereau, Caroline Bader, David Jervis https://lnkd.in/eeZKZBU3

25

3 commentaires

😮 𝗢𝘁𝗵𝗲𝗿 𝗵𝗲𝗺𝗼𝘀𝘁𝗮𝘁𝗶𝗰𝘀' 𝗱𝗮𝘁𝗮 𝗮𝗻𝗱 𝗽𝗲𝗿𝗳𝗼𝗿𝗺𝗮𝗻𝗰𝗲 𝗴𝗼𝘁 𝘆𝗼𝘂 𝗹𝗶𝗸𝗲 🤔? 𝗧𝗿𝘆 𝗠𝗼𝘇𝗮𝗶𝗸™ 𝗮𝗻𝗱 𝘀𝗲𝗲 𝘁𝗵𝗲 𝗱𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝗳𝗼𝗿 𝘆𝗼𝘂𝗿𝘀𝗲𝗹𝗳! 🩹📊 The lack of data on hemostatic devices can make it difficult to make informed decisions about which products to use. At NEPHROKIT, we're committed to supporting the performance of our products with scientific data. We recently presented at AFIDTN (French Dialysis Nurses Association) Annual Congress the results of 2 evaluations, including a registered research by Association ECHO, on our hemostatic patch, 𝘔𝘰𝘻𝘢𝘪𝘬™. The results showed a 45-60% reduction in post-dialysis compression time, going from 11 minutes to 5.5 minutes on average (https://lnkd.in/dir7WqGk). However, when we tried to compare these results with those of other hemostatics on the market, we were surprised by the lack of available data or the data that seemed to indicate a lack of effectiveness (interesting reading following the link below). That's why we're open to any serious proposal for a comparative study of 𝘔𝘰𝘻𝘢𝘪𝘬™ vs. other hemostatics. In the meantime, we're offering a set of 𝘔𝘰𝘻𝘢𝘪𝘬™ samples for you to judge its effectiveness yourself. Just PM me to get yours. 💡 NEPHROKIT: We constantly innovate to improve hemodialysis patients' quality of care and life. 🏭 All NEPHROKIT devices are made in France by GERGONNE INDUSTRIE - THE ADHESIVE SOLUTION . #dialysis #hemodialysis #vascular #access #vascularaccess #nephrologist #nurses #patients #patientcare #coagulation #fistula #patch #plaster #dressing #hemostatic #wearenephrokit #wearegergonne #madeinfrance Mokhtar Chawki

4

🧬 Latest Deals in Healthcare & Life Sciences 💼 💼 Extens has acquired a majority stake in Medicore, marking its first investment outside France, as part of its European expansion strategy, focusing on enhancing mental health solutions and EHRs for over 25,000 healthcare professionals. 💰 Kurma Partners has successfully closed €140m in its first closing of Biofund IV, aiming to raise a total of €250m by 2025 for innovative therapeutics investments. 💰 Healius has entered into a binding agreement to sell its Lumus Imaging subsidiary to Affinity Equity Partners for an enterprise value of A$965m (US$669m), enabling Healius to focus on its pathology strategy and enhance customer service and digital technologies. 🤝 Fondo Italiano d'Investimento SGR has invested €10m to acquire a minority stake in Intrauma, a developer of advanced orthopaedic medical devices, to support its growth targets and product expansion. 🇬🇧 Huma has acquired eConsult and launched Huma Workspace, aiming to create a comprehensive digital-first healthcare platform for the NHS. 💰 Asabys Partners has successfully closed its Sabadell Asabys Health Innovation Investments II Fund at €180m, surpassing its target of €150m, to invest in biopharma, medical devices, and digital health companies. 🔬 Bruker Corporation has acquired Dynamic Biosensors, enhancing its biophysical portfolio for biomolecular interaction analysis. 💼 Miura Partners has closed its fourth flagship fund, Miura Fund IV, at its hard cap of €475m, marking a total fundraising of €800m in 2024, with significant investments in family-owned businesses across healthcare, education, and other sectors 🩺 Mölnlycke Health Care has finalized its acquisition of PGF Industry Solutions, the Austrian manufacturer of Granudacyn wound cleansing and moistening solutions. Source : Investors in Healthcare ——— I am Alexis - French pharmacist turned entrepreneur. My company BTHT connects experts with consultants and investors in Life Sciences and Healthcare for expert calls and senior advisory. For more content like this 👇 Join 15K+ followers by clicking my name + follow 🔔 Join 1.4K+ subscribers to my weekly newsletter 💌

25

2 commentaires

🌟 AI and Robotics: Transforming Modern Medicine 🌟 20 Minutes France published an article about AWS re:Invent conference featuring our CTO, Nicolas Do Huu, PhD - here are the highlights for our English-speaking followers 😀 Amazon Web Services (AWS) showcased groundbreaking innovations in cloud and artificial intelligence (AI), including applications revolutionizing healthcare 🧬 Key Highlights from the article: ➡️ A New Industrial Era: As Nicolas explains, "AI opens the door to a new industrial revolution," making medical research faster, cost-efficient, and more accessible. ➡️ Diagnostics Revolution: AI tools are now enabling faster and more precise cancer diagnoses. ➡️ Faster Drug Discovery: generative AI tools halve the time needed to design new molecules, providing tailored solutions for specific projects. ➡️ Automation for Efficiency: robotics to automate chemical synthesis are essential to increasing speed and competitiveness in pharmaceutical production. 💡 These innovations are not just advancing technology but redefining modern medicine—bringing us closer to faster, more personalized treatments and reshoring pharma research in Europe. We’re thrilled to be part of this transformation and excited to continue pushing boundaries with AI and robotics in drug discovery. 👉 Read more about the impact of AI and the future of healthcare: https://lnkd.in/eQN9Z9A2

34

Do i have connections with Super users in ODDO ? Especially Financial Planning Modules ?

5

3 commentaires

Indeed, addressing the lack of precision in AI outputs is one of our key focuses at MAIA Medical Technologies , ensuring safety in the operating room.

6

The pandemic exposed overreliance on foreign suppliers for critical medical products. In this interview at SantExpo 2024, Christophe Eychenne-Baron of SEQENS Pharmaceutical Solutions and Victoire de Margerie of Rondol Group discuss the challenges and opportunities of localizing production of medicines in France, and their collaboration together to improve the bioavailability and formulation of drugs whilst decreasing costs and environmental footprint. (Transcription in English (PDF): https://lnkd.in/ew4JDmbh) https://lnkd.in/eA8RGTsY

4